NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026

NextCure, Inc.

Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.
Net loss for FY2025: $55.8M, roughly flat vs $55.7M in FY2024; R&D expenses rose to $44.9M.
SIM0505 (CDH6 ADC) Phase 1 dose escalation data and dose optimization start in ovarian cancer both expected Q2 2026.
LNCB74 (B7-H4 ADC) Phase 1 dose escalation update anticipated in second half of 2026.
Company expects current resources to fund operations into first half of 2027 through proof-of-concept for SIM0505.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

NextCure, Inc. reported the full year ended December 31, 2025 results: net income Net loss was $55.8 million.

Period: the full year ended December 31, 2025
Net income: Net loss was $55.8 million
Result: reported results

Exact text from the filing

NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December31, 2025.

View on SEC.gov

Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-024121

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.